Churchill Downs, GoodRx, and Schrödinger Report 2025 Full-Year Performance
Churchill Downs, GoodRx, and Schrödinger released their 2025 fourth-quarter and full-year financial results, highlighting a year of strategic expansion in gaming, healthcare technology, and AI-driven drug discovery. The reports reflect a broader market trend of resilient consumer spending in entertainment and the increasing integration of software-as-a-service (SaaS) models in specialized industries.
Beat this week
Last 7 days · Earnings
Impact 5.6/10 (+0.4 vs prior). Counts are stories in our record, not a market forecast.
Open the change reportCoverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 30 percentage points.
This story sits in Earnings — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.
Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.
Finance briefing
Key takeaways
- Churchill Downs, GoodRx, and Schrödinger released their 2025 fourth-quarter and full-year financial results, highlighting a year of strategic expansion in gaming, healthcare technology, and AI-driven drug discovery.
- The reports reflect a broader market trend of resilient consumer spending in entertainment and the increasing integration of software-as-a-service (SaaS) models in specialized industries.
In this briefing
Mentioned
Key Intelligence
Key Facts
- 1Churchill Downs reported record net income for FY 2025, driven by a 12% increase in Gaming segment revenue.
- 2GoodRx saw a 5% year-over-year increase in Monthly Active Consumers (MACs), reaching a new multi-year high.
- 3Schrödinger's software revenue grew by 15% in 2025, with over 1,800 active customers using its platform.
- 4Churchill Downs' TwinSpires segment benefited from a record $320M handle during the 151st Kentucky Derby.
- 5GoodRx's Pharma Manufacturer Solutions revenue now accounts for over 20% of its total quarterly revenue.
- 6Schrödinger ended 2025 with a cash position exceeding $450M, providing a multi-year runway for its internal pipeline.
| Metric | |||
|---|---|---|---|
| Primary Growth Driver | HRM Expansion | Pharma Solutions | Software Adoption |
| Market Focus | Gaming & Racing | Healthcare Tech | Biotech SaaS |
| 2025 Sentiment | Bullish | Neutral/Positive | Bullish |
Analysis
The 2025 fiscal year concluded with a series of robust earnings reports from Churchill Downs Incorporated (CHDN), GoodRx Holdings (GDRX), and Schrödinger (SDGR), each representing a distinct pillar of the modern economy: experiential entertainment, healthcare accessibility, and biotechnology software. These results, filed with the SEC on February 25, 2026, underscore the divergent paths of growth in a post-inflationary environment where operational efficiency and technological scaling have become the primary drivers of shareholder value.
Churchill Downs (CHDN) continued its aggressive expansion beyond its namesake racetrack, reporting a year defined by the successful integration of its Historical Racing Machine (HRM) facilities. The company’s strategy to diversify into high-margin gaming entertainment has paid off, with the Live Racing and Gaming segments benefiting from the 151st Kentucky Derby's record-breaking handle and the full-year contribution of new facilities like The Rose in Virginia. Analysts note that CHDN’s ability to maintain a dominant position in the niche HRM market provides a stable cash flow floor that traditional casino operators struggle to match, especially as the company leverages its TwinSpires platform to capture the growing online wagering demographic.
In the healthcare sector, GoodRx (GDRX) showed signs of a successful pivot toward its Pharma Manufacturer Solutions (PMS) business. After several years of navigating complex relationships with Pharmacy Benefit Managers (PBMs), GoodRx’s 2025 results indicate a stabilization of its core prescription discount business. The company’s focus on 'Integrated Savings Programs' has allowed it to recapture Monthly Active Consumers (MACs) who had previously migrated to competing platforms. The 2025 performance suggests that GoodRx is successfully transitioning from a simple coupon provider to a comprehensive healthcare affordability platform, though it still faces headwinds from rising competition in the direct-to-consumer pharmacy space.
What to Watch
Schrödinger (SDGR) provided a compelling look at the intersection of software and drug discovery. The company reported steady growth in its software revenue, driven by the widespread adoption of its physics-based modeling platform by top-tier pharmaceutical companies. However, the real story for Schrödinger in 2025 was the progress of its internal drug discovery pipeline and its collaborative programs. With several proprietary candidates moving deeper into clinical trials, the company’s drug discovery revenue remains lumpy but carries significant upside potential from milestone payments. Investors are increasingly viewing Schrödinger as a 'picks and shovels' play for the AI-driven biotech revolution, where its software provides recurring revenue while its pipeline offers high-beta growth opportunities.
Looking ahead to 2026, the market will be watching for how these companies manage capital allocation. Churchill Downs is expected to continue its HRM rollout, while GoodRx must prove it can sustain MAC growth in a crowded market. For Schrödinger, the focus will remain on clinical data readouts that could validate its software-first approach to drug development. Collectively, these earnings reports suggest a market that is rewarding companies with clear technological moats and the ability to generate consistent cash flow in their respective niches.
Cite This Page
"Churchill Downs, GoodRx, and Schrödinger Report 2025 Full-Year Performance." Finance Intelligence Brief, February 26, 2026. https://getfinancebrief.com/story/chdn-gdrx-sdgr-2025-earnings-briefing
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |